Precision oncolytic immunotherapy for mesothelioma and renal cell carcinoma
Bidragets beskrivning
Our immune system has the potential to protect us from cancer, but tumor cells have many strategies to hide from immune cells or turn off the immune attack. Immunotherapy is a way of helping our immune system to recognise the cancer and give it the right weapons to fight and destroy it. Immunotherapies have shown great promise and increased survival of cancer patients, but only for a fraction of patients. There is an urgent need for therapies that more precisely recognize a patient tumor, more efficient therapies that can overcome the tumor defence mechanisms and better pre-clinical models to test the therapies before they are used on patients. We have developed three novel technologies and a pipeline to address these challenges and aim to develop precision therapies against two tumor models, mesothelioma and renal cell carcinoma.
Visa merStartår
2023
Slutår
2027
Beviljade finansiering
Övriga uppgifter
Finansieringsbeslutets nummer
355107
Vetenskapsområden
Farmaci
Forskningsområden
Farmasia
Identifierade teman
cancer